Jérôme Fayette

Université Claude Bernard Lyon 1 — France

Medicine · Health Sciences

49h-index25.6kcitations387works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(171), Cancer Immunotherapy and Biomarkers(128), Lung Cancer Treatments and Mutations(113), Lung Cancer Research Studies(40), Cancer Diagnosis and Treatment(38)

Publications384 total

Figure S1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Data1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Figure S2 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
European Journal of Cancer·2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Future Oncology·2025· 2 citedOpen Access
Defining a need for rapid response and practical guidance for recurrent and metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) management in France: A Delphi consensus
PLoS ONE·2025· 1 citedOpen Access
966P IMMUNONET: A proof of concept phase II evaluating NP137 as add on therapy in solid tumors under standard immunotherapies: Interim analysis of primary and secondary refractory cohorts
Annals of Oncology·2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Value in Health·2025
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
Future Oncology·2025· 3 citedOpen Access
FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).
Journal of Clinical Oncology·2025
IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies.
Journal of Clinical Oncology·2025
Supplementary Figure S1 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
Supplementary Figure S3 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
Data from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
Supplementary Figure S4 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
Supplementary Figure S2 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
Supplementary Figure S5 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
page 1 of 20Next →

Frequent Co-authors

J. Guigay(16), Caroline Even(16), Robert I. Haddad(15), Kevin J. Harrington(14), Lisa Licitra(13), Makoto Tahara(13), Robert L. Ferris(12), Maura L. Gillison(12), Everett E. Vokes(11), Nabil F. Saba(11), George R. Blumenschein(10), A. Dimitrios Colevas(8), Stefan Kasper(8), Francis P. Worden(8), Naomi Kiyota(8), Mark Lynch(7), Jean‐Yves Blay(7), Didier Cupissol(7), Neal Ready(5), Fabrice Barlési(5)